{"id":"W3208029444","doi":"10.1007/s12325-021-01898-1","title":"Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Actelion Pharmaceuticals; Seoul St. Mary's Hospital, Catholic University of Korea; Universitaire Ziekenhuizen Leuven, KU Leuven; Guangdong Provincial People's Hospital; Universität Wien; Peking Union Medical College; Karl-Franzens-Universität Graz; University of Ottawa; Medizinische Universität Graz; Peking Union Medical College Hospital; Changi General Hospital; Royal Adelaide Hospital; Samsung; Aarhus Universitetshospital; Shanghai Pulmonary Hospital; Centre Hospitalier Universitaire de Toulouse; Universität Greifswald; Seoul National University Hospital; Renji Hospital; Seoul National University; Catholic University of Korea; Aarhus Universitet; Jewish General Hospital; Medizinische Universität Wien; University of Alberta; Rigshospitalet","keywords":"Tolerability; Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Placebo; Pulmonary hypertension; Clinical trial; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002010547,0.0002658266,0.0006432668,0.00007727427,0.00009896157,0.00003828191,0.00009667387,0.00009011765,0.00003095969],"category_scores_gemma":[0.00007925142,0.0001709221,0.00001379116,0.0003161615,0.0001234564,0.0005735983,0.0001189133,0.0002315314,0.000002227619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006099654,"about_ca_system_score_gemma":0.0001113536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000125698,"about_ca_topic_score_gemma":0.0004021132,"domain_scores_codex":[0.997846,0.0001972434,0.0003702063,0.0008449621,0.0004019978,0.0003396077],"domain_scores_gemma":[0.998799,0.0002233223,0.00008808779,0.0004366255,0.0002502753,0.0002026612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08939899,0.004052647,0.8207352,0.00003355593,0.00007058476,0.005531326,0.00007306393,0.000004648125,0.002635963,0.000003901323,0.000005066846,0.07745505],"study_design_scores_gemma":[0.03931316,0.001736851,0.9569235,0.0004890923,0.00001647946,0.0001248554,0.00004870039,0.0001451781,0.0005765809,0.00009123876,0.0003273571,0.0002069673],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857843,0.01226944,0.000003597138,0.0006082818,0.0001064838,0.0009452873,0.00009643662,0.00001784475,0.0001683646],"genre_scores_gemma":[0.9816054,0.0168363,0.0005823938,0.0003644809,0.00003742168,0.00002771643,0.00044082,0.00002690566,0.00007854815],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1361883,"threshold_uncertainty_score":0.6970001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03548669979077369,"score_gpt":0.3073673866782115,"score_spread":0.2718806868874378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}